Exosome-Mediated Reporter Gene Assays

Q: How do your dual-luciferase assays control for differences in transfection efficiency between wells?

The dual-luciferase system intrinsically controls for this. Firefly luciferase (the experimental reporter) and Renilla luciferase (the normalization control) are measured sequentially from the same well. The firefly/Renilla ratio cancels out any well-to-well variation in cell number, transfection efficiency, or viability because both reporters are equally affected by these variables. Only cargo-specific effects on the firefly reporter remain in the normalized ratio. We additionally require a Renilla CV of <15% across all experimental wells as a quality gate.

Q: What controls do you include to prove the reporter modulation is really from exosome-delivered cargo?

Every experiment includes three essential controls. First, a seed region-mutated reporter construct in which the miRNA/siRNA binding sites are disrupted—this should show no modulation, confirming sequence specificity. Second, scrambled cargo sequence controls using mEVs loaded with non-targeting sequences. Third, vesicle-depleted supernatant controls to rule out soluble factors. Only experiments where the wild-type reporter shows significant modulation while all three controls remain at baseline are reported as positive functional delivery.

Q: Can you test whether endogenously loaded mEV miRNAs are functional, or only engineered cargo?

Both. For endogenous miRNA profiling, we first perform small RNA sequencing on your mEV preparation to identify and quantify the miRNA cargo. We then use bioinformatic target prediction to identify candidate target genes, construct dual-luciferase reporters for the top candidates, and test each one experimentally. For engineered cargo (siRNA, mRNA, etc.), we design the reporter construct to match your cargo sequence directly. The assay workflow is the same in both cases.

Q: What is the difference between a transient luciferase readout and a permanent Cre-loxP reporter, and when should I use each?

Transient dual-luciferase assays provide a quantitative, dose-dependent readout within 24–72 hours and are ideal for potency comparisons, dose–response curves, and screening applications where cargo delivery efficiency is moderate to high. Permanent Cre-loxP or CRISPR reporters accumulate signal irreversibly over days to weeks, making them suitable for detecting rare functional transfer events, tracking cell fate after cargo delivery, or quantifying cumulative effects in long-term co-culture models. We often use both in sequence—luciferase for rapid screening, Cre-loxP for definitive confirmation.

Q: Can microbial vesicle RNA survive the extracellular environment long enough to be functionally delivered?

Yes, but protection varies by vesicle type. OMVs from Gram-negative bacteria provide robust RNA protection due to their LPS-rich outer membrane and periplasmic compartment. CMVs from Gram-positive probiotics offer moderate protection that can be enhanced by formulation. We can include RNase protection assays as part of the functional validation package to directly measure the proportion of vesicle-protected vs. unprotected RNA cargo in your preparation.

Q: How do reporter gene assays integrate with other functional characterization services?

Reporter gene assays typically follow exosome uptake assays that confirm internalization, and precede downstream phenotypic assays such as cell migration, proliferation, or immunomodulation studies. This sequential approach—uptake → functional cargo delivery → phenotypic consequence—builds a complete mechanistic narrative. We offer integrated packages that combine all three stages for a comprehensive functional characterization of your mEVs.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

Detecting that a vesicle has been internalized is only half the story—the biologically decisive question is whether the internalized cargo actually reaches its intracellular target and produces a measurable functional effect. At Creative BioMart Microbe, our exosome-mediated reporter gene assays close this gap by providing direct, quantitative evidence that microbial extracellular vesicle (mEV) cargo—whether endogenous miRNA, engineered siRNA, or recombinant mRNA—is functionally delivered to recipient cells and modulates target gene expression. Using dual-luciferase reporter systems, fluorescent protein readouts, and CRISPR-based permanent lineage tracing, we build an unbroken chain of evidence from vesicle internalization through cargo release to downstream gene regulation.

Our platform supports the full diversity of microbial vesicle engineering strategies, from naturally loaded probiotic mEVs carrying regulatory small RNAs to engineered OMVs loaded with therapeutic siRNA or CRISPR guide RNAs. Each assay is configured around your specific cargo, target gene, and cell type, with rigorous controls that distinguish functional delivery from non-specific effects. Whether you are validating a novel mEV-based drug delivery system, confirming the mechanism of action of a naturally occurring probiotic vesicle cargo, or benchmarking engineered vesicle variants for cargo loading efficiency, our reporter gene assays provide the quantitative readout that uptake imaging alone cannot deliver. Contact us to discuss reporter gene assay design for your mEV project.

Multi-stage workflow diagram for exosome-mediated reporter gene assays showing vesicle cargo design, cell co-incubation, dual-luciferase signal measurement, fluorescence reporter activation, and quantitative functional delivery reporting.
Figure 1. Exosome-mediated reporter gene assay workflow from cargo engineering and vesicle loading through co-incubation with reporter cell lines to quantitative readout of functional gene regulation.

Services

Service Workflow

Our reporter gene assay workflow is configured around your specific cargo and target gene, with parallel assay arms for both functional transfer confirmation and mechanistic specificity controls.

Five-step horizontal workflow showing Cargo & Reporter Design, Vesicle Loading & QC, Cell Co-Incubation, Dual-Luciferase or Fluorescence Readout, and Quantitative Functional Analysis.

Inquiry

Service Details

3D illustration of a dual-luciferase reporter assay showing a 96-well plate with luminescent wells, with firefly and Renilla luciferase enzyme structures and a bar chart comparing normalized luciferase activity across experimental groups.

Dual-Luciferase Reporter Gene Silencing Assays

We construct reporter plasmids with your target gene 3’UTR cloned downstream of firefly luciferase, co-transfected with a constitutively expressed Renilla luciferase normalization control. Co-incubation with cargo-loaded mEVs produces quantitative luminescence ratios that directly measure target gene repression. The dual-reporter design controls for cell number, transfection efficiency, and non-specific cytotoxicity in a single well.

3D illustration of fluorescent reporter cells switching from red to green fluorescence upon functional exosome cargo delivery, with flow cytometry scatter plots showing population shifts.

Fluorescent Reporter Activation & Lineage Tracing

For permanent readout of functional cargo delivery, we employ Cre-loxP and CRISPR-based reporter cell lines that undergo irreversible fluorescent protein switching (e.g., DsRed → eGFP) upon successful cargo transfer. Flow cytometry and fluorescence microscopy quantify the percentage of cells that received functionally active cargo, enabling rare-event detection and single-cell resolution analysis.

3D illustration of a miRNA-mRNA interaction schematic with a miRNA-loaded vesicle delivering its cargo to the RISC complex, which then binds the target mRNA 3'UTR and suppresses translation, shown alongside a decreasing luminescence curve.

Endogenous miRNA Functional Transfer Validation

For mEVs carrying naturally loaded small RNAs, we first profile the vesicle miRNA cargo by small RNA sequencing, then systematically test the top candidate miRNAs against predicted target genes using dual-luciferase reporter constructs. Target site mutagenesis controls (seed region mutations that abolish miRNA binding) confirm sequence-specific regulation and rule out off-target effects.

3D illustration of engineered exosomes loaded with siRNA duplexes, showing the siRNA being released inside a target cell, loading into the RISC complex, and cleaving target mRNA with a dose-response curve overlay.

Engineered Cargo Delivery (siRNA/mRNA/CRISPR) Validation

We validate the functional delivery of exogenously loaded siRNA, mRNA, or CRISPR ribonucleoprotein complexes by mEVs. For siRNA cargo, sequence-specific target gene knockdown is quantified by dual-luciferase reporter and confirmed by qPCR and western blot. For mRNA cargo, translation into functional protein is detected by fluorescence or enzymatic activity. Scrambled sequence controls are included in every experiment.

3D illustration of a multi-panel dose-response experimental design with increasing vesicle concentrations along the x-axis and decreasing luciferase signal on the y-axis, showing sigmoidal curve fitting and EC50 calculation.

Dose–Response & Cargo Loading Efficiency Analysis

We titrate mEV dose across a defined concentration range and measure reporter gene modulation at each point, generating full dose–response curves with calculated EC₅₀ values. By normalizing the functional signal to the absolute quantity of cargo molecules loaded per vesicle (determined by qPCR or digital droplet PCR), we calculate cargo-specific functional transfer efficiency—a critical parameter for comparing vesicle engineering strategies.

Service Specifications & QC Standards

Instrumentation & Capability

Luminometry: Multi-mode plate readers with dual-injector capability for firefly and Renilla luciferase sequential measurement.
Flow cytometry: Multi-parameter analysis of fluorescent reporter activation with single-cell resolution.
Fluorescence microscopy: Automated imaging for reporter cell visualization and colony-level analysis of permanent lineage tracing.
qPCR/ddPCR: Absolute quantification of miRNA and siRNA cargo molecules per vesicle for loading efficiency normalization.
Small RNA sequencing: Illumina-based sRNA-seq for endogenous mEV miRNA cargo profiling.
Western blot: Target protein knockdown confirmation at the protein level.

Typical Data Range

Dual-luciferase reporter sensitivity: Detection of ≥30% target gene repression at 5–10 μg/mL mEV protein.
Maximum observable repression: >90% firefly/Renilla ratio reduction in optimized systems.
Fluorescent reporter switching: Detection of ≥0.1% reporter-positive cells in Cre-loxP systems.
Dose–response dynamic range: 4–5 log orders of mEV concentration.
EC₅₀ precision: ±0.3 log units for dose–response curve fitting (R² > 0.95).
Cargo quantification sensitivity: Down to 10 copies of miRNA per vesicle by ddPCR.
Target gene knockdown confirmation: ≥50% mRNA reduction by qPCR and corresponding protein decrease by western blot.

Turnaround Time

Project Type	Timeline
Reporter construct design and cloning	2–3 weeks
Single miRNA-target dual-luciferase validation	2–3 weeks
Endogenous miRNA cargo profiling (sRNA-seq) + target screen	4–6 weeks
Engineered cargo (siRNA) functional delivery validation	2–4 weeks
Cre-loxP/CRISPR permanent reporter assay	3–5 weeks
Full dose–response + cargo loading efficiency package	4–6 weeks
Integrated functional delivery characterization package	6–10 weeks

Timelines may vary based on construct complexity, cell line requirements, and number of targets tested.

Deliverables

Reporter construct map and sequence documentation (plasmid maps, GenBank files).
Dual-luciferase raw data: Firefly and Renilla luminescence values with normalized ratios.
Flow cytometry data: FCS files with gating strategy for fluorescent reporter-positive populations.
Microscopy images: Fluorescence micrographs of reporter cells with quantification.
Cargo quantification report: miRNA/siRNA copies per vesicle by qPCR or ddPCR.
Dose–response analysis: Curve fits, EC₅₀ values, and functional transfer efficiency calculations.
qPCR and western blot confirmation data for target gene knockdown.
Methods documentation suitable for publication.

Quality Control

Reporter construct sequence verification by Sanger sequencing before transfection.
Transfection efficiency ≥70% for all reporter cell line experiments.
Renilla luciferase CV <15% across all wells in an experiment (confirms consistent transfection).
Scrambled/mutant seed region control: <10% reporter modulation confirms sequence specificity.
Vesicle-depleted supernatant control: <5% reporter modulation confirms vesicle-dependence.
Endotoxin monitoring on all mEV preparations used for functional assays.
Intra-assay CV ≤12%; inter-assay CV ≤20% for normalized luciferase ratios.
MISEV2023-compliant documentation of all vesicle preparation and assay parameters.

Sample Requirements

Required Information	Optional Information	Not Accepted
mEV source species, strain, and preparation method Cargo type (endogenous miRNA, engineered siRNA, mRNA, CRISPR RNP) Target gene(s) and desired regulatory direction (knockdown or activation) Target cell type for functional delivery Prior vesicle characterization data (NTA, TEM, protein concentration) Cargo loading method (if engineered)	Target gene 3’UTR sequence (if available) for reporter construct design Small RNA-seq data for endogenous miRNA cargo candidates Prior uptake assay data in the same cell type Desired statistical power and biological replicate number Publication target journal for figure formatting	Uncharacterized vesicle preparations without size and concentration data Crude culture supernatant without enrichment Samples with endotoxin levels above the acceptable threshold for cell-based assays Vesicles exposed to RNase without appropriate controls Degraded or aggregated vesicle preparations Samples shipped without cold-chain documentation

Recommended Sample Quantity by Assay:

Assay Type	Minimum	Recommended
Single dual-luciferase reporter assay (per target)	30 μg total protein	60–100 μg total protein
sRNA-seq cargo profiling	10 μg total protein	20–50 μg total protein
Multi-target reporter screen (5–10 targets)	100 μg total protein	200–500 μg total protein
Engineered cargo validation (per cargo)	50 μg total protein	100–200 μg total protein
Cre-loxP/CRISPR permanent reporter assay	20 μg total protein	50–100 μg total protein
Full dose–response + loading efficiency package	150 μg total protein	300–500 μg total protein

Storage & Shipping: Ship mEV suspensions in sterile, nuclease-free PBS on dry ice. For RNA cargo preservation, include RNase inhibitor if vesicles were not treated with RNase post-isolation. Provide documentation of any cargo loading steps, including electroporation parameters or transfection reagents used. For endogenous miRNA studies, we recommend providing parallel aliquots for sRNA-seq profiling and functional assay use to ensure cargo composition matching. Our Exosome Isolation & Purification Services and Exosome Characterization & Quality Analytics are available for upstream processing.

Inquiry

Our Advantages

Closed-Loop Functional Validation — We link mEV uptake to sequence-specific reporter modulation, delivering complete evidence chains from vesicle entry to target gene regulation for peer review and regulatory acceptance.
Rigorous Specificity Controls — Every assay includes seed-mutated constructs, scrambled cargo, and vesicle-depleted supernatant controls to confirm sequence-specific delivery and exclude non-specific effects.
Cargo Loading Normalization — We normalize all functional readouts to absolute cargo molecules per vesicle via qPCR/ddPCR, enabling direct comparison across engineering strategies.
Microbial RNA Stability Expertise — Our RNase-free workflows protect microbial vesicle RNA from co-purified nucleases and LPS-associated degradation throughout isolation and assay.
Permanent Lineage Tracing — Cre-loxP and CRISPR reporters accumulate signal over time, detecting rare cargo transfer events that transient assays miss during candidate screening.

Applications

3D icon showing a dual-luciferase reporter plasmid with miRNA binding sites, with a miRNA-loaded vesicle approaching, and a bar chart showing reduced luminescence compared to mutated control.

miRNA Target Deconvolution

Identify which of the hundreds of miRNAs carried by your mEV preparation functionally regulate which target genes in recipient cells.

3D icon of an engineered vesicle carrying siRNA duplexes, docking at a target cell, with the siRNA being released and silencing a disease-associated gene shown as a decreasing activity curve.

RNA Therapeutic Delivery Validation

Quantitatively validate that your mEV-based siRNA, ASO, or mRNA delivery system achieves sequence-specific target gene modulation with defined potency.

3D icon showing a comparison matrix with differently engineered vesicles being tested against the same reporter assay, with a ranked bar chart of functional delivery efficiency.

Vesicle Engineering Benchmarking

Compare functional delivery efficiency across different loading methods, surface modifications, or production strains using cargo-normalized reporter readouts.

3D icon of a probiotic bacteria-derived vesicle interacting with intestinal epithelial cells, with the vesicle's miRNA cargo being tracked to a target gene involved in barrier function.

Probiotic Mechanism of Action

Demonstrate that probiotic-derived mEV miRNAs functionally regulate host gene expression, establishing the molecular basis for health benefit claims.

Case Study

Case Study 1: Live-Cell Reporter Validation of Exosome Secretion and Uptake Dynamics

The researchers engineered pHluo_M153R-CD63, a stabilized pH-sensitive fluorescent reporter that enables real-time tracking of exosome secretion and recipient cell uptake. The M153R mutation markedly improved protein stability and brightness over the original pHluo-CD63, permitting stable lentiviral expression and long-term live imaging. In HT1080 cells, the reporter exclusively labeled small extracellular vesicles (peak ~105 nm) and colocalized with exosomal markers TSG101 and Alix. Rab27a knockdown significantly reduced both small EV secretion and extracellular reporter deposition, confirming MVB-origin specificity. Live imaging further revealed that migrating cells secrete exosomes at their leading edge and subsequently exhibit pathfinding behavior along these trails in 2D and 3D environments. A dual-color pHluo_M153R-CD63-mScarlet variant additionally enabled simultaneous visualization of MVB trafficking before plasma membrane fusion and endosome acidification following exosome uptake.

Live confocal microscopy of dual-color pHluo_M153R-CD63-mScarlet reporter showing MVB trafficking to cell protrusions, fusion events, filopodia-mediated exosome uptake, and subsequent endosome acidification.
Figure 2. Dual reporter reveals MVB transport before fusion and endosome acidification after uptake. (Sung, et al. 2020)

FAQs

Q: How do your dual-luciferase assays control for differences in transfection efficiency between wells?

A: The dual-luciferase system intrinsically controls for this. Firefly luciferase (the experimental reporter) and Renilla luciferase (the normalization control) are measured sequentially from the same well. The firefly/Renilla ratio cancels out any well-to-well variation in cell number, transfection efficiency, or viability because both reporters are equally affected by these variables. Only cargo-specific effects on the firefly reporter remain in the normalized ratio. We additionally require a Renilla CV of <15% across all experimental wells as a quality gate.

Q: What controls do you include to prove the reporter modulation is really from exosome-delivered cargo?

A: Every experiment includes three essential controls. First, a seed region-mutated reporter construct in which the miRNA/siRNA binding sites are disrupted—this should show no modulation, confirming sequence specificity. Second, scrambled cargo sequence controls using mEVs loaded with non-targeting sequences. Third, vesicle-depleted supernatant controls to rule out soluble factors. Only experiments where the wild-type reporter shows significant modulation while all three controls remain at baseline are reported as positive functional delivery.

Q: Can you test whether endogenously loaded mEV miRNAs are functional, or only engineered cargo?

A: Both. For endogenous miRNA profiling, we first perform small RNA sequencing on your mEV preparation to identify and quantify the miRNA cargo. We then use bioinformatic target prediction to identify candidate target genes, construct dual-luciferase reporters for the top candidates, and test each one experimentally. For engineered cargo (siRNA, mRNA, etc.), we design the reporter construct to match your cargo sequence directly. The assay workflow is the same in both cases.

Q: What is the difference between a transient luciferase readout and a permanent Cre-loxP reporter, and when should I use each?

A: Transient dual-luciferase assays provide a quantitative, dose-dependent readout within 24–72 hours and are ideal for potency comparisons, dose–response curves, and screening applications where cargo delivery efficiency is moderate to high. Permanent Cre-loxP or CRISPR reporters accumulate signal irreversibly over days to weeks, making them suitable for detecting rare functional transfer events, tracking cell fate after cargo delivery, or quantifying cumulative effects in long-term co-culture models. We often use both in sequence—luciferase for rapid screening, Cre-loxP for definitive confirmation.

Q: Can microbial vesicle RNA survive the extracellular environment long enough to be functionally delivered?

A: Yes, but protection varies by vesicle type. OMVs from Gram-negative bacteria provide robust RNA protection due to their LPS-rich outer membrane and periplasmic compartment. CMVs from Gram-positive probiotics offer moderate protection that can be enhanced by formulation. We can include RNase protection assays as part of the functional validation package to directly measure the proportion of vesicle-protected vs. unprotected RNA cargo in your preparation.

Q: How do reporter gene assays integrate with other functional characterization services?

A: Reporter gene assays typically follow exosome uptake assays that confirm internalization, and precede downstream phenotypic assays such as cell migration, proliferation, or immunomodulation studies. This sequential approach—uptake → functional cargo delivery → phenotypic consequence—builds a complete mechanistic narrative. We offer integrated packages that combine all three stages for a comprehensive functional characterization of your mEVs.

References:

Sung, B. H., et al. (2020). A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells. Nature Communications, 11, 2092.

Services

Inquiry